Merck KGaA Upgrades Profit Guidance Amid Life Science and Electronics Growth

Merck KGaA has raised its profit guidance for 2026 due to strong demand in its Life Science and Electronics units. The company posted better-than-expected quarterly results, citing a gain in demand for drug manufacturing supplies and semiconductor materials.

The new adjusted EBITDA guidance range for 2026 is between €5.9 billion and €6.3 billion, surpassing the previous range of €5.7 billion to €6.1 billion. This is up from last year's €6.1 billion in adjusted EBITDA.

The Life Science unit saw an organic growth rate of approximately 8.3% in lab supplies, particularly Process Solutions. The Electronics unit benefited from sustained demand for semiconductor materials, especially those used for advanced AI nodes.